367 related articles for article (PubMed ID: 8632346)
21. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
[TBL] [Abstract][Full Text] [Related]
22. Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis.
Kyoi T; Oka M; Noda K; Ukai Y
Life Sci; 2004 Aug; 75(15):1833-42. PubMed ID: 15302227
[TBL] [Abstract][Full Text] [Related]
23. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.
Piazza GA; Thompson WJ; Pamukcu R; Alila HW; Whitehead CM; Liu L; Fetter JR; Gresh WE; Klein-Szanto AJ; Farnell DR; Eto I; Grubbs CJ
Cancer Res; 2001 May; 61(10):3961-8. PubMed ID: 11358813
[TBL] [Abstract][Full Text] [Related]
24. The phosphodiesterase 3 inhibitor cilostamide enhances inotropic responses to glucagon but not to dobutamine in rat ventricular myocardium.
Juan-Fita MJ; Vargas ML; Hernández J
Eur J Pharmacol; 2005 Apr; 512(2-3):207-13. PubMed ID: 15840406
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of apoptosis induced by purine nucleosides in astrocytes.
Di Iorio P; Kleywegt S; Ciccarelli R; Traversa U; Andrew CM; Crocker CE; Werstiuk ES; Rathbone MP
Glia; 2002 May; 38(3):179-90. PubMed ID: 11968056
[TBL] [Abstract][Full Text] [Related]
26. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.
Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC
Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089
[TBL] [Abstract][Full Text] [Related]
27. Activation of A(3) receptors by endogenous adenosine inhibits synaptic transmission during hypoxia in rat cortical neurons.
Hentschel S; Lewerenz A; Nieber K
Restor Neurol Neurosci; 2003; 21(1-2):55-63. PubMed ID: 12808203
[TBL] [Abstract][Full Text] [Related]
28. Regulation of adenosine concentration and cytoprotective effects of novel reversible adenosine deaminase inhibitors.
Barankiewicz J; Danks AM; Abushanab E; Makings L; Wiemann T; Wallis RA; Pragnacharyulu PV; Fox A; Marangos PJ
J Pharmacol Exp Ther; 1997 Dec; 283(3):1230-8. PubMed ID: 9399998
[TBL] [Abstract][Full Text] [Related]
29. Nitric oxide-mediated regulation of connexin43 expression and gap junctional intercellular communication in mesangial cells.
Yao J; Hiramatsu N; Zhu Y; Morioka T; Takeda M; Oite T; Kitamura M
J Am Soc Nephrol; 2005 Jan; 16(1):58-67. PubMed ID: 15537869
[TBL] [Abstract][Full Text] [Related]
30. Effect of adenosine deaminase inhibition upon human lymphocyte blastogenesis.
Carson DA; Seegmiller JE
J Clin Invest; 1976 Feb; 57(2):274-82. PubMed ID: 176177
[TBL] [Abstract][Full Text] [Related]
31. Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor.
Silver PJ; Dundore RL; Bode DC; de Garavilla L; Buchholz RA; van Aller G; Hamel LT; Bacon E; Singh B; Lesher GY
J Pharmacol Exp Ther; 1994 Dec; 271(3):1143-9. PubMed ID: 7996419
[TBL] [Abstract][Full Text] [Related]
32. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
33. VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors.
Favot L; Keravis T; Holl V; Le Bec A; Lugnier C
Thromb Haemost; 2003 Aug; 90(2):334-43. PubMed ID: 12888882
[TBL] [Abstract][Full Text] [Related]
34. In vivo effects of phosphodiesterase inhibition on basal cyclic guanosine monophosphate levels in the prefrontal cortex, hippocampus and cerebellum of freely moving rats.
Marte A; Pepicelli O; Cavallero A; Raiteri M; Fedele E
J Neurosci Res; 2008 Nov; 86(15):3338-47. PubMed ID: 18655195
[TBL] [Abstract][Full Text] [Related]
35. The cyclic GMP-specific phosphodiesterase inhibitor, sildenafil, stimulates human sperm motility and capacitation but not acrosome reaction.
Lefièvre L; De Lamirande E; Gagnon C
J Androl; 2000; 21(6):929-37. PubMed ID: 11105920
[TBL] [Abstract][Full Text] [Related]
36. Selective inhibition by NPT 15392 of lymphocyte cyclic GMP phosphodiesterase.
Coffey RG; Hartley L; Polson JB; Krzanowski JJ; Hadden JW
Biochem Pharmacol; 1984 Nov; 33(21):3411-7. PubMed ID: 6093811
[TBL] [Abstract][Full Text] [Related]
37. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.
Ahn HS; Bercovici A; Boykow G; Bronnenkant A; Chackalamannil S; Chow J; Cleven R; Cook J; Czarniecki M; Domalski C; Fawzi A; Green M; Gündes A; Ho G; Laudicina M; Lindo N; Ma K; Manna M; McKittrick B; Mirzai B; Nechuta T; Neustadt B; Puchalski C; Pula K; Zhang H
J Med Chem; 1997 Jul; 40(14):2196-210. PubMed ID: 9216839
[TBL] [Abstract][Full Text] [Related]
38. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
39. NO-cGMP pathway increases the hyperpolarisation-activated current, I(f), and heart rate during adrenergic stimulation.
Herring N; Rigg L; Terrar DA; Paterson DJ
Cardiovasc Res; 2001 Dec; 52(3):446-53. PubMed ID: 11738061
[TBL] [Abstract][Full Text] [Related]
40. Endogenous nitric oxide attenuates beta-adrenoceptor-mediated relaxation in rat aorta.
Kang KB; van der Zypp A; Majewski H
Clin Exp Pharmacol Physiol; 2007; 34(1-2):95-101. PubMed ID: 17201742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
